Concr

Looking forward to speaking at the upcoming Investival Showcase ahead of the Jefferies London Healthcare Conference! Give me a shout if you're around that week, and you're also invited to watch the Concr showcase: 📍 Tobacco Dock, London - Healthtech & Medtech Stage 🗓️ 18 November 2024 🕛 12.30pm #Investival #biotech #medtech #healthtech #digitalhealth #JefferiesHealthcare LSX - partnering for Life Science eXecutives

Discover Concr, the next Cambridge spinout changing the story of cancer! 🚀 Concr leverages astrophysics computational frameworks to interlink disparate and messy oncology data, enabling scientists to identify and develop drug response biomarkers. Its algorithms model tumour complexity and predict their evolution, leading to more accurate patient responses, effective treatments, while minimising side effects. Matthew Foster, Concr's Co-founder, says, “Our vision is to ensure precision oncology reaches the widest population." To find out more about Concr and the way its team is changing the story of cancer, click here: https://vist.ly/3mk3i3b #CancerResearch #Healthcare #LifeSciences #UniversityOfCambridge #Innovation

Join us tomorrow at #BioFuture2024! Looking forward to joining this terrific group of people to discuss how we can sort out #cancer. #Innovation #Future #CancerResearch Concr

We all hate the thought of the “C word”, and all envisage (or have personal experience of) what treatment is like, with drugs not always effective and undertaking invasive and devastating surgery and chemotherapy. For this reason I was excited to read an article about a digital cancer drug treatment this morning. Also, importantly for our government colleagues who would prefer Australian researchers focus on primarily on applied research, this research was the result of applying a technology developed in astronomy - another great example of how discovery-based research can find amazing and unexpected impacts in every day life. The article was about a UK-funded research project, presented is Spain last week, showing exciting developments in harnessing the power of digital twins to predict how well patients might respond to specific cancer therapies. This innovation could lead to improved personalised drugs and treatment plans and improve outcomes by simulating the complex interactions within the body, allowing doctors to make more informed decisions. The project’s technology, called FarrSight®-Twin, which is based on algorithms used by astrophysicists to discover black holes, was presented last week at a symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The findings were presented by Dr Uzma Asghar, Co-founder and Chief Scientific Officer at Concr and a consultant medical oncologist, currently working at The The Royal Marsden NHS Foundation Trust, London, UK. In the project each digital twin was created from biological data from thousands of patients with cancer who have been treated in different ways. This information is combined to recreate the cancer of a real patient with molecular data on their tumour. This twin makes it possible to predict how a patient is likely to respond to a treatment, meaning researchers can simulate patient trials at a much earlier stage in drug development and re-run the simulation multiple times to test out different scenarios and maximise the likelihood of success. It’s incredible to see how digital technology and science are converging to create smarter, more effective solutions for one of the world’s most challenging health issues. Looking forward to seeing how this research progresses and helps us consider how to exploit new digital tools, such as AI in digital twins, to make the process of cancer treatment and drug discovery quicker, easier, cheaper and most importantly improve quality of life. Note: This work has not yet being peer reviewed, but I will watch with interest and hope. See the full media release and details via scimex at https://lnkd.in/gTyWST-B Scimex.org - Breaking science news for Australia and New Zealand #DigitalHealth #CancerResearch #Innovation #PersonalisedMedicine

Algorithms used by astrophysicists to discover black holes have helped to create FarrSight-Twin, a technology that recreates clinical trials of new treatments using ‘digital twins’ of real cancer patients. FarrSight-Twin was presented on October 24, 2024 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. According to the researchers, this approach could be used by cancer researchers to run virtual clinical trials before testing new treatments on patients. It could also be used alongside clinical trials with a digital twin for each patient taking part, which together could form a control group for any trial. It might also mean that patients could have different treatments tested on their digital twin to help select the most suitable treatment ahead of time. The research was presented by Dr Uzma Asghar, co-founder and chief scientific officer at Concr and a consultant medical oncologist. Learn more here 👇 https://lnkd.in/ecVFskxs #theengineer #digitaltwins #clinical #medical #treatments

📣 Not one, but 𝐓𝐖𝐎 presentations at this week's #ENA2024 symposium! Delighted to share that our most recent study in Acute Myeloid Leukaemia has been accepted as a 𝒍𝒂𝒕𝒆-𝒃𝒓𝒆𝒂𝒌𝒊𝒏𝒈 𝒂𝒃𝒔𝒕𝒓𝒂𝒄𝒕. This aggressive #BloodCancer saw promising therapeutic developments over recent years, but better stratification methodologies are needed to identify individual patient responders. We will present our recent data on the use of FarrSight®-Twin alongside the current European LeukemiaNet (ELN) protocol. 🩸 Are you working in #AML? We'd love to hear from you! And for a deeper dive into FarrSight®-Twin for individualised response prediction in other cancers, come and see Dr Uzma Asghar's talk on Friday 25th. Looking forward to connecting with cancer researchers at the symposium and sharing ideas 💡! EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research #Innovation #CancerResearch #AI #Technology #FromCosmologytoOncology

Introducing 10 Cambridge spinouts changing the story of cancer. 🌟 A brilliant idea for helping cancer patients is just that - an idea - until it is put into practice. Turning research into something that can improve patient outcomes and benefit healthcare systems around the world is not easy. At Cambridge Enterprise, we support spinouts from the University of Cambridge through their commercialisation journey. Being part of the UK’s leading life sciences cluster provides plenty of inspiration, access to investors and talent, and the guidance of others who have gone before. Meet 10 of our spinouts, all committed to making a real difference: • T-Therapeutics Ltd • Concr • 52North - creators of Neutrocheck® • PhoreMost Ltd • STORM Therapeutics Limited • Verinnogen • Spirea • biomodal • PharmEnable Therapeutics • Astex Pharmaceuticals 👉🏼 Read more about how they are are driving the future of cancer treatment: https://vist.ly/3mj67du #CancerResearch #Healthcare #LifeSciences #UniversityOfCambridge #Innovation

This Wednesday we'll be at BioIndustry Association (BIA) #TechbioUK event - come and say hello to our CEO Irina Babina (and maybe get a sneak peak of the fresh new FarrSight® look 🤫🤫 ) #LifeSciences #Innovation #Data #AI #FromCosmologytoOncology

 Proud to announce that I'll be joining a panel at #BioFuture2024! 🎤 This great event explores the latest topics shaping the future of #healthcare alongside industry leaders and trailblazing companies (😉😉). You can still register here 👉 www.BioFuture.com I hope to see many of you there! 📅 28-30 October 2024 📍 New York City 🎙️ Panel Discussion: The Fight against Cancer: Where are the Next Transformational Breakthroughs Going to Come From? #PrecisionOncology #Innovation #LifeSciences #FromCosmologytoOncology

✨ We're excited about these 𝐢𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐞𝐯𝐞𝐧𝐭𝐬 on the horizon: #TechBioUK 24 organised by BioIndustry Association (BIA) to grow TechBio sector 📅 16 October 2024 📍 London, UK #ENA2024 where we will present our latest results, thanks to EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI), American Association for Cancer Research 📅 23-25 October 2024 📍 Barcelona, Spain Investival Showcase to showcase Concr during the 𝑳𝒐𝒏𝒅𝒐𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆𝒔 𝑾𝒆𝒆𝒌 📅 18 November 2024 📍 London, UK Get in touch if you're attending - would be great to share ideas and build connections! https://concr.co/contact #PrecisionOncology #Innovation #Biomarkers #FromCosmologytoOncology